Hostname: page-component-cb9f654ff-pvkqz Total loading time: 0 Render date: 2025-08-28T09:24:23.175Z Has data issue: false hasContentIssue false
  • English
  • Français

Perception of equivalent doses of neuroleptic drugs

Published online by Cambridge University Press:  02 January 2018

R. Mullen ,
A.W. Caan  and
S. Smith
R. Mullen
Affiliation:
The Maudsley Hospital, London SE5 8AZ
A.W. Caan
Affiliation:
The Maudsley Hospital, London SE5 8AZ
S. Smith
Affiliation:
The Maudsley Hospital, London SE5 8AZ
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

An anonymous questionnaire was sent to 67 senior and junior psychiatrists enquiring about their perception of equivalent antipsychotic dosages of three commonly used neuroleptic drugs. Thirty-one questionnaires were returned and revealed a wide variation in perceived potencies for the specific drugs. Increased experience in psychiatry was not associated with a decreased variation. On average clinicians saw haloperidol and flupenthixol decanoate as substantially less potent, relative to chlorpromazine, than the available literature would suggest.

Information

Type
Original papers
Information
Psychiatric Bulletin , Volume 18 , Issue 6 , June 1994 , pp. 335 - 337
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 1994

References

Association of the British Pharmaceutical Industry (1990) ABPI Data Sheet Compendium 1993–94, 695.Google Scholar
British National Formulary (1993) 25, 149–155.Google Scholar
Forster, P. (1989) Neuroleptic equivalence. The Pharmaceutical Journal, September, 431–432.Google Scholar
Krakowski, M.I., Kunz, M., Czobar, P. & Volavka, J. (1993) Long-term high-dose neuroleptic treatment: who gets it and why? Hospital and Community Psychiatry, 44, 640–644.Google Scholar
Peroutka, S.J. & Snyder, S.H. (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, a-adrenergic, and histamine receptors to clinical potency. American Journal of Psychiatry, 137, 1518–1522.Google Scholar
Rey, M., Schulz, P., Costa, C., Dick, P. & Tissot, R. (1989) Guidelines for the dosage of neuroleptics. 1: Chlorpromazine equivalents of orally administered neuroleptics. International Clinical Psychopharmacology, 4, 95–104.Google Scholar
Shulz, P., Rey, M., Dick, P. & Tissot, R. (1989) Guidelines for the dosage of neuroleptics. 2: Changing from daily oral to long acting injectable neuroleptics. International Clinical Psychopharmacology, 4, 105–114.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.